The MYH7B antibody targets the protein encoded by the MYH7B gene, a member of the myosin heavy chain (MYH) family. Myosin heavy chains are critical components of sarcomeres in muscle cells, contributing to contractile functions. MYH7B, also classified as MYH14. is part of the class II myosin group and is expressed in specific tissues, including skeletal muscle, heart, and certain smooth muscles. Unlike its closely related isoform MYH7 (β-myosin heavy chain), which is predominantly cardiac, MYH7B has a broader expression pattern and may play roles in both muscle contraction and non-muscle cellular processes.
Research on MYH7B has gained attention due to its potential involvement in diseases. Mutations in MYH7B have been linked to inherited cardiomyopathies, such as hypertrophic cardiomyopathy (HCM), and certain cancers. The antibody serves as a vital tool for detecting MYH7B protein levels in tissues, enabling studies on its expression patterns, localization, and functional mechanisms. It is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence.
Commercial MYH7B antibodies are typically developed using immunogenic peptide sequences unique to the protein, ensuring specificity. Validation steps include testing on knockout cell lines or tissues to confirm minimal cross-reactivity. Understanding MYH7B's role through antibody-based research could provide insights into disease pathways and therapeutic targets, particularly in cardiac and oncological contexts. Ongoing studies aim to clarify its regulatory mechanisms and interactions within cellular networks.